

Cosmetic benefits of astaxanthin on humans subjects*

Kumi Tominaga, Nobuko Hongo, Mariko Karato and Eiji Yamashita✉

Fuji Chemical Industry Co. Ltd., Kamiichi, Toyama, Japan

Two human clinical studies were performed. One was an open-label non-controlled study involving 30 healthy female subjects for 8 weeks. Significant improvements were observed by combining 6 mg per day oral supplementation and 2 ml (78.9 μ M solution) per day topical application of astaxanthin. Astaxanthin derived from the microalgae, *Haematococcus pluvialis* showed improvements in skin wrinkle (crow's feet at week-8), age spot size (cheek at week-8), elasticity (crow's feet at week-8), skin texture (cheek at week-4), moisture content of corneocyte layer (cheek in 10 dry skin subjects at week-8) and corneocyte condition (cheek at week-8). It may suggest that astaxanthin derived from *H. pluvialis* can improve skin condition in all layers such as corneocyte layer, epidermis, basal layer and dermis by combining oral supplementation and topical treatment. Another was a randomized double-blind placebo controlled study involving 36 healthy male subjects for 6 weeks. Crow's feet wrinkle and elasticity; and transepidermal water loss (TEWL) were improved after 6 mg of astaxanthin (the same as former study) daily supplementation. Moisture content and sebum oil level at the cheek zone showed strong tendencies for improvement. These results suggest that astaxanthin derived from *Haematococcus pluvialis* may improve the skin condition in not only in women but also in men.

Key words: astaxanthin, healthy human subjects, *Haematococcus pluvialis*, skin condition

Received: 17 October, 2011; **accepted:** 01 March, 2012;
available on-line: 17 March, 2012

INTRODUCTION

Astaxanthin, is widely and naturally distributed in marine organisms, including crustaceans such as shrimps and crabs; and fish such as salmon and sea bream. In fact, it is one of the oldest carotenoids isolated and identified from lobster, *Astacus gammarus* (Kuhn *et al.*, 1938). Astaxanthin was first commercially used for pigmentation only in the aquaculture industry. Later in 1991, when the biological activity from potent antioxidative properties and the physiological function as a vitamin A precursor in fish and mammals (rats) were reported, astaxanthin as a food supplement started gaining acceptance (Miki, 1991; Matsuno, 1991). Further reports suggest that astaxanthin does not have any pro-oxidative nature like β -carotene and lycopene (Martin *et al.*, 1999) and its potent anti-oxidative property is exhibited on the cell membrane (Goto *et al.*, 2001). Among various health-promoting effects of astaxanthin have been reported (Yuan *et al.*, 2010) including anti-inflammatory effects (Lee *et al.*, 2003). There are few studies on the skin. In terms of

dermatological actions, suppression of hyper-pigmentation (Yamashita, 1995) and inhibitions of melanin synthesis and photoaging (Arakane, 2002) have been reported. We have previously reported three clinical studies to evaluate either topical or oral supplementation effects of astaxanthin derived from the microalgae *H. pluvialis*. The first as a small pilot study was the repeated topical application test of a cream containing not only astaxanthin but other active ingredients and effective base materials (Seki *et al.*, 2001). A double blind placebo controlled study using a dietary supplement containing astaxanthin and tocotrienol from palm oil was the second (Yamashita, 2002). In the third study, we reported the effects of a dietary supplement containing only astaxanthin in a single blind placebo controlled study (Yamashita, 2006). All these studies were either oral supplementation or topical application trials using female subjects. Here we report an open-labeled non-controlled clinical study by combining both oral supplementation and topical treatment of astaxanthin involving healthy female subjects and a randomized double-blind placebo controlled study by astaxanthin oral supplementation involving 36 healthy male subjects.

METHOD

Materials. The material for oral supplementation contained AstaREAL® Oil 50F (Fuji Chemical Industry Co., Ltd., Toyama, Japan), 5% w/w astaxanthin *H. pluvialis* extract and canola oil as soft gel capsules. Each capsule contained 3 mg of astaxanthin. Identical placebo capsules for control were prepared with only canola oil in soft capsules.

The product for external use had 0.094% AstaTROL™-Hp (5% w/w astaxanthin *H. pluvialis* extract, Fuji Chemical Industry Co., Ltd., Toyama, Japan) resulting in 78.9 μ M astaxanthin solution without any other active ingredient and effective base materials.

Subjects and study design. As far as the first study (Study-1) is concerned, thirty (30) healthy women in Japan, aged 20 to 55 years old, participated after obtaining their informed consent. Astaxanthin wash-out period was eight weeks before start. One capsule as internal supplementation was administered to each subject twice daily, after breakfast and dinner respectively. 1ml of the topical application was applied onto the whole face of each subject twice daily every morning and evening after washing. Test duration was eight weeks starting from October, 2008. Measurements

✉ e-mail: yamashita@fujichemical.co.jp

*Presented at the 16th International Symposium on Carotenoids, 17–22 July, 2011, Kraków, Poland

Abbreviations: TEWL, transepidermal water loss.

of each test item were performed at three points, at the beginning of the study, after four weeks and after eight weeks. The study was open-label and non-controlled.

On another study (Study-2), thirty-six (36) healthy men in Japan, aged 20 to 60 years old, participated after obtaining their informed consent. The subjects were divided into the two groups, astaxanthin supplemented ($n=18$) and placebo ($n=18$). After an eight week wash-out period one capsule was orally administered to each subject twice daily, after breakfast and dinner respectively. The test period was six weeks starting from October, 2008. Measurements of each test item were performed at the beginning of the study and after six weeks. The study was performed under a randomized double-blind and placebo controlled manner.

Conditions of measurement. The measurements were performed 15 minutes after the subjects were allowed to rest in a seated position after washing their faces in an environmental test room conditioned to $20\pm2^{\circ}\text{C}$ (or $68\pm3.6^{\circ}\text{F}$) room temperature and $45\pm10\%$ relative humidity in the both studies.

Measurement parameters. Wrinkle. Skin surface photographs for crow's feet condition evaluation were recorded using the Facial Stage (Moritex Co., Tokyo, Japan). Wrinkle topography measurements were made from negative skin replicas of the left crow's feet and calculated by the ASA-03RXD (Asahibiomed Co., Ltd., Yokohama, Japan) image analysis based on six parameters — deepest point of the deepest wrinkle, mean depth of the deepest wrinkle, maximum width of the deepest wrinkle, area ratio of all wrinkles, mean depth of all wrinkles and volume ratio of all wrinkles.

Elasticity. Skin elasticity of the left crow's feet area was measured by ASA-GP1 (Asahibiomed Co., Ltd.).

Age spot. Skin surface photographs for cheek condition evaluation were also recorded using the Facial Stage with normal and UV lamps. Comparison of the most outstanding age spot in the left cheek between 0 and




Figure 1. Skin surface photographs and replica images of crow's feet.

8 weeks were determined by image analysis using ImageJ (NIH, USA).

Skin texture. Skin topography for cheek (left side) condition evaluation were determined with replicas by the ASA-03RXD image analysis based on four parameters — number of texture, mean depth of texture, volume ratio of texture/volume ratio of all texture and projection number of texture. Corneocyte of the left cheek was collected by Scotch tape stripping and was applied to hematoxylin-eosin stain. The area was calculated by ImageJ analysis on a prepared slide at a magnification of 200 times.

Moisture content. Skin moisture contents of the left crow's feet for wrinkle evaluation and cheek for skin texture evaluation, respectively, were recorded using the ASA-M2 (Asahibiomed Co., Ltd.).

Sebum oil: Skin sebum oil content at the left cheek was measured by the SEBU sheet around the nose.

Transepidermal Water Loss (TEWL): TEWL at the left cheek was measured by the ASA-CT1 (Asahibiomed Co., Ltd.).

Wrinkle, elasticity, age spots, skin texture and moisture content were measured for Study-1. And wrinkle,




Figure 2. Wrinkle parameters from replica image analysis.

By paired t-test: * $p<0.05$ ** $p<0.01$.

elasticity, moisture content, sebum oil and TWEL were measured for Study-2.

RESULTS

Study-1

Wrinkle, moisture content & elasticity. Figure 1 shows skin surface photographs and replica images of the crow's feet area in two subjects at week-0 and -8. Visual wrinkle reductions were observed respectively. Significant improvements on four parameters were observed. Deepest point of the deepest wrinkle (at week-8 with $p<0.01$), mean depth of the deepest wrinkle (at week-4 and -8 with $p<0.01$), maximum width of the deepest wrinkle (at week-8 with $p<0.01$) and mean depth of all wrinkles (at week-4 and -8 with $p<0.05$) out of six as shown in Fig. 2. Moisture content of corneocyte layer in the left crow's feet did not show any significant differences before and after the treatment (not shown). Elasticity of crow's feet area significantly improved at both week-4 and -8 (Fig. 3).

Age spot. Figure 4 shows skin surface photographs with both normal and UV lamps of the cheek area in two subjects at week-0 and -8. Visual age spot reductions were observed in the both subjects. The age spot area was significantly treated at week-8 as shown in Fig. 5.

Skin texture & moisture content. Figure 6 shows skin topographic replica images of the cheek in two subjects at week-8. Visual rough skin improvements were observed in the both subjects. There was a significant improvement on the parameter, mean depth of texture (at week-8 with $p<0.01$) out of four as shown in Fig. 7. Total area of the corneocyte at week-8 significantly improved from the start period (Fig. 8). Moisture content




Figure 3. Skin elasticity of crow's feet.
By paired *t*-test: * $p<0.05$ ** $p<0.01$.




Figure 4. Skin surface photographs with both normal and UV lamps of cheek.




Figure 5. Age spot area of cheek.
By paired *t*-test: ** $p<0.01$




Figure 6. Skin topographic replica images of cheek.




Figure 7. Mean depth of texture of cheek.
By paired *t*-test: * $p<0.05$ ** $p<0.01$.




Figure 8. Size of total area of corneocyte.
By paired *t*-test: * $p<0.05$.

of corneocyte layer in the cheek among all subjects did not show any significant differences. However, in ten dry skin subjects out of thirty showed a significant increase with $p<0.05$ at week-8 (not shown).

Study-2

Wrinkle. As shown in Fig. 9, significant improvements in two parameters "Area ratio of all wrinkles" and




Figure 9. Wrinkle test parameters from replica image analysis. Unpaired *t*-test: **p*<0.05; N.S., not significant.




Figure 10. Skin elasticity of crow's feet. Unpaired *t*-test: **p*<0.05.

"Volume ratio of all wrinkles" out of six parameters at week-6 were observed compared to the start.

Moisture content. Moisture content at the crow's feet did not show any significant differences before and after the administration (not shown). However, the moisture content of the cheek did show a tendency (*p*=0.08) increase among the selected subjects who had dry skin less than 17 μ S of moisture content at the beginning of the study (data not shown).




Figure 11. Sebum oil of cheek. Unpaired *t*-test: N.S., not significant.




Figure 12. Transepidermal water loss (TEWL) of cheek. Unpaired *t*-test: ***p*<0.01.

Elasticity. Elasticity of crow's feet area significantly improved at week-6 compared to the start (Fig. 10).

Sebum oil. Sebum oil of the cheek showed a tendency (*p*=0.085) of decrease at week-6 compared to the start (Fig. 11).

TEWL. Figure 12 shows a significant improvement on TEWL at week-6 compared to week-0.

DISCUSSION

We studied the cosmetic effects of astaxanthin, a strong carotenoid antioxidant, from the two viewpoints of administration technique and sex. Study-1 was performed to evaluate the impact of combination of both oral supplementation and topical administration in an open-label non-controlled test involving female subjects. Significant improvements as a deep impact were observed in skin wrinkle (crow's feet at week-8), age spot size (cheek at week-8), elasticity (crow's feet at week-8), skin texture (cheek at week-4), moisture content of corneocyte layer (cheek in 10 dry skin subjects at week-8) and corneocyte condition (cheek at week-8). Combination technique may be much beneficial for the skin. And Study-2 was performed to evaluate the efficacy in male subjects by oral supplementation under a randomized

double-blind placebo controlled condition. Significant improvements were observed in wrinkle and elasticity of crow's feet and TWEL at cheek at week-6 compared to start. Tendencies of improvement in moisture content and sebum oil at cheek were also observed. Astaxanthin supplementation exhibited cosmetic benefits in not only female but male subjects.

The wrinkle parameters used in the present studies has been authorized by the Japanese Cosmetic Science Society (Task Force Committee for Evaluation of Anti-aging Function, 2007) as a guideline for the functional assessment of anti-wrinkle product. The Committee prescribes that a product can be effective in wrinkle reduction in the case of significant improvement from at least one parameter. It is also provided that any parameters are equivalent. Significant improvements from four parameters in Study-1 and from two parameters in Study-2 were observed respectively. The female subjects in Study-1 were unrestrained in any cosmetic behavior such as skin care or dietary supplement. Bedside, the male subjects in Study-2 were absent from any cosmetic behavior. It seems that a double administration by combining oral supplementation and topical treatment should be recommended for wrinkle reduction and oral supplementation might be more potent than topical treatment. The mechanism of action of wrinkle reduction by astaxanthin could be explained as a dermis condition improvement through collagen fiber recovery. Astaxanthin promotes collagen fiber recovery by protecting the dermal layer from singlet oxygen damage which has been substantiated by an *in vitro* study using human dermal fibroblasts (Tominaga *et al.*, 2009). There are the reasons why the moisture content of corneocyte layer in crow's feet was not significantly changed before and after the test and the ASA-GP is available to a measurement of dermic elasticity. Elasticity was also improved as a result of collagen fiber recovery both in Study-1 & -2. Significant inhibition of melanogenesis in age spots were observed in the same manner as the other reports (Yamashita, 1995; Arakane, 2002) by suppressing the oxidative polymerization in melanocytes and inflammation in epidermis in Study-1. Regarding improvement of rough skin by astaxanthin treatment on the mean depth of texture and the size of total area of the corneocyte in Study-1, it's the first finding. It seems that the improvements resulted in the moisture content increase in the cheek among dry skin subjects. The mean moisture content in the all subjects at start was approximately 20 μ S in Study-1. In general, the range of moisture content of dry skin is 12–15 μ S. A significant increase was observed in ten subjects whose moisture content was less than 17 μ S at the start. In Study-2 moisture content of the cheek show a strong tendency increase among the selected subjects less than 17 μ S at the start. Topical treatment might be more deeply involved in the improvement of rough skin than oral supplementation. Corneocyte consists of the dead epidermal cells. Astaxanthin treatment might normalize

the corneocyte conditions protecting the keratinocyte differentiation and cornification from oxidative damages such as inflammation in epidermis. Excess oxidized sebum oil causes rough skin and aging odor. It's well-known that men have more sebum oil production than women. Astaxanthin supplementation may help to reduce rough skin and aging odor protecting the sebum oil from peroxidation. TEWL is a marker for the barrier functions in corneocyte layer. It also seems that the significant TWEL improvements resulted in normalizing the corneocyte condition. Atopic skin patients who have high TEWL may be treated by astaxanthin supplementation.

In conclusion these results may suggest that astaxanthin derived from *H. pluvialis* can improve skin condition in all layers such as corneocyte layer, epidermis, basal layer and dermis by combining both oral supplementation and topical treatment and oral supplementation of astaxanthin can improve the skin condition in not only women but also men.

REFERENCES

- Arakane K (2002) Superior skin protection *via* astaxanthin. *Carotenoid Science* **5**: 21–24.
- Goto S, Kogure K, Abe K, Kimata K, Kitahama K, Yamashita E, Terada H (2001) Efficient radical trapping at the surface and inside the phospholipid membrane is responsible for highly potent anti-oxidative activity of the carotenoid astaxanthin. *Biochim Biophys Acta* **1515**: 251258.
- Kuhn R, Sorensen NA (1938) The coloring matters of the lobster (*ASTACUS GAMMARUS* L.). *Z. Angew Chem* **51**: 465–466.
- Lee SJ, Bai SK, Lee KS, Namkoong S, Na HJ, Ha KS, Han JA, Yim SV, Chang K, Kwon YG, Lee SK, Kim YM (2003) Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I κ B kinase-dependent NF- κ B activation. *Mol Cells* **16**: 97–105.
- Martin HD, Ruck C, Schmidt M, Sell S, Beutner S, Mayer B, Walsh R (1999) Chemistry of carotenoid oxidation and free radical reactions. *Pure Appl Chem* **71**: 2253–2262.
- Matsuno T (1991) Xanthophylls as precursors of retinoids. *Pure Appl Chem* **63**: 81–88.
- Miki W (1991) Biological functions and activities of animal carotenoids. *Pure Appl Chem* **63**: 141–146.
- Seki T, Sueki H, Kono H, Suganuma K, Yamashita E (2001) Effects of astaxanthin from *Haematococcus pluvialis* on human skin-patch test; skin repeated application test; effect on wrinkle reduction. *Fragrance J* **12**: 98–103.
- Task Force Committee for Evaluation of Anti-aging Function (2007) Guideline for evaluation of anti-wrinkle products in “Guidelines for evaluation of cosmetic functions”. *J Jpn Cosmet Sci Soc* **31**: 411–431.
- Tominaga K, Hongo N, Karato M, Yamashita E (2009) Protective effects of astaxanthin against singlet oxygen induced damage in human dermal fibroblasts *in vitro*. *Food Style* **21** **13**: 84–86.
- Yamashita E (1995) Suppression of post-UVB hyperpigmentation by topical astaxanthin from krill. *Fragrance J* **14**: 180–185.
- Yamashita E (2002) Cosmetic benefit of dietary supplements including astaxanthin and tocotrienol on human skin. *Food Style* **21** **6**: 112–117.
- Yamashita E (2006) The effects of a dietary supplement containing astaxanthin on skin condition. *Carotenoid Science* **10**: 91–95.
- Yuan JP, Peng J, Yin K, Wang JH (2010) Potential health-promoting effects of astaxanthin: a high-value carotenoid mostly from microalgae. *Mol Nutr Food Res* **54**: 1–16.